comparemela.com

Latest Breaking News On - Khurram jamil - Page 1 : comparemela.com

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended .

Richard uihleinChris calabreseJack callicuttKhurram jamilKevin gardnerBenjamins carsonPol boudesCompany annual report on formBelapectin programDrug administrationCompany contactExchange commissionGalectin therapeutics incChief medical officerFast track designationData safety

Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K -March 29, 2024 at 07:59 am EDT

Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31,.

Khurram jamilChris calabreseBenjamins carsonJack callicuttJoel lewisPol boudesRichard uihleinKevin gardnerCompany annual report on formExchange commissionCompany contactBelapectin programDrug administrationGalectin therapeutics incGalectin therapeutics reportsProvides business update

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M D as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target .

United statesPolf boudesChris calabreseKhurram jamilJack callicuttKevin gardnerCompany annual report on formGalectin therapeutics incKing edward medical university at lahoreOrganon pharmaceuticals united statesClinical developmentMallinckrodt pharmaceuticalsIkaria incSeaton hall universityCompany contactDrug administration

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting

/PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three scientific abstracts evaluating.

United statesJuan carlosq velezPrnewswire mallinckrodtDerek belzHanim wadeiJamilk terlipressinDanielj specialeKhurram jamilMallinckrodt hospital products incOchsner healthGreen room communicationsNational organization for rare disordersMallinckrodt pharmaceuticalsExchange commissionClinical development critical careAmerican society of nephrology

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

/PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from.

United statesBritish columbiaUnited kingdomPalo altoRonaldj wongJacquelineg olearyDerek belzRobertj wongPrnewswire mallinckrodtPaulj thuluvathRyan taylorDanielj specialeKhurram jamilPrashant pandyaMallinckrodt pharmaceuticalsStanford university school of medicine

vimarsana © 2020. All Rights Reserved.